Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase

Experimental Hematology

Volumn 43, Issue 3, 2015, Pages 207-214

  Yamanishi, Miho ^a   Narazaki, Hidehiko ^a   Asano, Takeshi ^a  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CLOFARABINE; DEOXYCYTIDINE KINASE; HISTONE H3; HISTONE H4; MELATONIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; RNA; VORINOSTAT; ADENINE NUCLEOTIDE; ANTINEOPLASTIC AGENT; ARABINONUCLEOSIDE;

ARTICLE; CONTROLLED STUDY; DCK GENE; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; EPIGENETICS; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC50; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T CELL LEUKEMIA; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CELL LINE, TUMOR; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA; MELATONIN; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84925182912     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.11.001     Document Type: Article

References (30)

1. Holleman A., Cheok M.H., den Boer M.L., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004, 351:533-542.
2. Rose J.B., Coe I.R. Physiology of nucleoside transporters: back to the future. Physiology (Bethesda) 2008, 23:41-48.
3. Jeha S., Gandhi V., Chan K.W., et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004, 103:784-789.
4. Parker W.B., Shaddix S.C., Chang C.H., et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res 1991, 51:2386-2394.
5. Bonate P.L., Arthaud L., Cantrell W.R., Stephenson K., Secrist J.A., Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006, 5:855-863.
6. Gandhi V., Plunkett W., Bonate P.L., et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 2006, 12:4011-4017.
7. Nagai S., Takenaka K., Nachagari D., et al. Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity. Cancer Res 2011, 71:1781-1791.
8. Mansson E., Flordal E., Liliemark J., et al. Down-regulatoin of deoxycytidine kinase in leukemic cell resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludareabine resistance. Biochem Pharmacol 2003, 65:237-247.
9. Al Madhoun A.S., van der Wilt C.L., Loves W.J., et al. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000. Biochem Pharmacol 2004, 68:601-609.
10. Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001, 15:875-890.
11. Eden A., Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
12. Asano T., Nakamura K., Fujii H., et al. Altered expression of topoisomerase Iiα contributes to etoposide cross-resistant K562/MX2 cell line by aberrant methylation. Br J Cancer 2005, 92:1486-1492.
13. Nowak S.J., Corces V.G. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet 2004, 20:214-220.
14. Berger S.L. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002, 12:142-148.
15. Lewy A.J. Melatonin and human chronobiology. Cold Spring Harb Symp Quant Biol 2007, 72:623-636.
16. Martin V., Sanchez-Sanchez A.M., Herrera F., et al. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer 2013, 108:2005-2012.
17. Niles L.P., Pan Y., Kang S., Lacoul A. Melatonin induces histone hyperacetylation in the rat brain. Neurosci Lett 2013, 541:49-53.
18. Zhao L., Wientjes M.G., Au J.L. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004, 10:7994-8004.
19. Peters G.J., Hodzic J., Ortega B., et al. Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase. Nucleosides Nucleotides Nucleic Acids 2010, 29:408-413.
20. Candelaria M., de la Cruz-Hernandez E., Taja-Chayeb L., et al. DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. PLoS One 2012, 7:e29181.
21. Asano T., Tsutsuda-Asano A., Fukunaga Y. Indomethacin overcomesdoxorubicin resistance by decreasing intracellular content ofglutathione and its conjugates with decreasing expression ofgamma-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells. Cancer Chemother Pharmacol 2009, 64:715-721.
22. Wang J., Xiao X., Zhang Y., et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 2012, 53:77-90.
23. Yu C.C., Pan S.L., Chao S.W., et al. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I. Biochem Pharmacol 2014, 90:320-330.
24. de Wolf C., Jansen R., Yamaguchi H., et al. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther 2008, 7:3092-3102.
25. Huang Y., Greene E., Murray Stewart T., et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results inreexpression of aberrantly silenced genes. Proc Natl Acad Sci U S A 2007, 104:8023-8028.
26. Ougolkov A.V., Bilim V.N., Billadeau D.D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008, 14:6790-6796.
27. Huo H., Magro P.G., Pietsch E.C., Patel B.B., Scotto K.W. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res 2010, 70:8726-8735.
28. Ma J., Dong C., Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010, 17:523-531.
29. Puppin C., Passon N., Lavarone E., et al. Levels of histone acetylation in thyroid tumors. Biochem Biophys Res Commun 2011, 411:679-683.
30. Xiaomeng X., Ming Z., Jiezhi M., Xiaoling F. Aberrant histone acetylation and methylation levels in woman with endometriosis. Arch Gynecol Obstet 2013, 287:487-494.